PaxMedica (NASDAQ:PXMD) Issues Earnings Results

PaxMedica (NASDAQ:PXMD) released its quarterly earnings results on Friday. The company reported ($0.39) earnings per share for the quarter, reports.

PaxMedica Stock Down 1.0 %

PXMD opened at $0.10 on Monday. PaxMedica has a 12-month low of $0.07 and a 12-month high of $10.26. The firm’s fifty day moving average price is $0.19 and its 200 day moving average price is $0.34.

About PaxMedica

PaxMedica, Inc, a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. Its lead product candidate is PAX-101 that is in Phase 3 clinical trials, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, fragile X syndrome, human African trypanosomiasis (HAT), and fragile X-associated tremor/ataxia syndrome.